- Decisions coming soon on steel mill, smelter in New Madrid (11/17/17)1
- Cape man accused of secretly recording women, posting to porn site (11/22/17)
- Thankful People: Kirsten Strebe recovers from traumatic car accident, brain injury (11/23/17)
- Cape attorney Brandon Cooper to run for judge (11/20/17)2
- Thankful People: Moore family counts its blessing after harrowing accident (11/23/17)
- Cape native co-directs Thanksgiving-related indie film, 'Drinksgiving' (11/17/17)
- State audit: Bollinger County tax levies violate state law; county commission disagrees (11/17/17)3
- Deal Finder brings 'unique' shopping to Cape Girardeau (11/24/17)
- The Tungsten Groove to release first album featuring original songs (11/17/17)
- 1 dead, 3 hurt in accident on Highway 72 (11/19/17)
Negotiated drugs not beneficial
To the editor:U.S. Rep. Jo Ann Emerson's call for the federal government to negotiate Medicare drug prices directly with pharmaceutical companies is seriously misguided ("Emerson sees big problems coming in health care," July 6).
First, it is not even clear that allowing the government to negotiate prices would save any money. As the nonpartisan Congressional Budget Office recently concluded, "Government price negotiation would not yield lower drug prices compared to current law."
Second, the only government program that has been successful at reducing drug costs through negotiations is the VA, which doesn't negotiate at all. Rather, it imposes price controls. Under the VA model, drug companies must sell their products to the government at a price that is at least 24 percent less than the non-federal average manufacturer price.
If similar price controls were imposed under Medicare Part D, the end result would be less patient choice and stifled innovation into new drugs.
PETER PITTS, Director, Center for Medicine in the Public Interest, New York